rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    SLXN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      12 Health Care Stocks Moving In Wednesday's After-Market Session
      8h agoBenzingaACTUSLXN
      Silexion announces 1-for-24 reverse stock split effective Tuesday
      Nov 9Investing.comSLXN
      Silexion Therapeutics Announces 1-for-24 Reverse Share Split

      Trading on a split-adjusted basis will begin at market open on November 11, 2026. This adjustment is expected to help Silexion regain compliance with the Nasdaq minimum bid price requirement, enhance its market position, and support its clinical progress with SIL204 Grand Cayman, Cayman Islands, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-dr

      Nov 9Yahoo FinanceSLXN
      Silexion Therapeutics Shareholders Approve Major Capital Restructuring

      Tipranks Press Release.

      Oct 27The Globe and MailSLXN
      12 Health Care Stocks Moving In Friday's After-Market Session - Silexion Therapeutics (NASDAQ:SLXN), Lexa

      Gainers Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 11.0% to $0.17 during Friday's after-market session. The company's market cap stands at $2.4 million. Lexaria Bioscience (NASDAQ:LEXX) stock

      Oct 16BenzingaSLXN
      Silexion Therapeutics Begins Phase 2/3 SIL204 Trial With First Patient Dosed in Pancreatic Cancer

      Silexion Therapeutics has moved SIL204 into active patient treatment, beginning a multinational Phase 2/3 study that will evaluate the RNAi candidate alongside standard chemotherapy in locally advanced pancreatic cancer. Key Investor TakeawaysSilexion Therapeutics (NASDAQ:SLXN) has successfully dosed the first patient in its Phase 2/3 SIL204 trial, moving the programme into active clinical execution.

      Sep 30Yahoo FinanceSLXN
      Silexion Therapeutics Announces Warrant Inducement Financing Deal

      Detailed price information for Silexion Therapeutics Corp (SLXN-Q) from The Globe and Mail including charting and trades.

      Sep 30The Globe and MailSLXN
      Silexion raises $837,000 through warrant exercise at reduced price
      Sep 29Investing.comSLXN
      12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Silexion Therapeutics (NASDAQ:SLXN), Summi

      Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 26.8% to $0.32 during Tuesday's pre-market session. The company's market cap stands at $1.3 million. Summit Therapeutics (NASDAQ:SMMT) stock rose 16.34%

      Sep 29BenzingaSLXNSMMT
      Silexion Therapeutics Announces Exercise of Warrants

      Cayman Islands, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding series E warrants to purchase up to an aggregate of 3,216,928 of the Company’s ordinary shares originally issued in August 2026 having a reduced exercise price of

      Sep 29Yahoo FinanceSLXN
      Silexion Therapeutics (SLXN) Stock Soars 61% After Hours: Here's What's Going On - Silexion Therapeutics

      Silexion Therapeutics shares jump after hours on positive SIL204 preclinical findings for KRAS-driven cancers.

      Sep 29BenzingaSLXN
      12 Health Care Stocks Moving In Monday's After-Market Session - Silexion Therapeutics (NASDAQ:SLXN), Chem

      Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 27.1% to $0.31 during Monday's after-market session. The market value of their outstanding shares is at $1.4 million. Chemomab Therapeutics (NASDAQ:CMMB)

      Sep 28BenzingaACTUCMMBSLXN
      Silexion reports preclinical data on SIL204 delivery mechanism
      Sep 28Investing.comSLXN
      Silexion Therapeutics Shareholders Reject Capital Structure Changes

      Tipranks Press Release.

      Sep 26The Globe and MailSLXN
      Silexion Therapeutics Receives Nasdaq Bid Price Deficiency Notice

      Detailed price information for Silexion Therapeutics Corp (SLXN-Q) from The Globe and Mail including charting and trades.

      Sep 26The Globe and MailSLXN
      Silexion Therapeutics Corp (SLXNW) Stock Price, News, Quote & History - Yahoo Finance

      Find the latest Silexion Therapeutics Corp (SLXNW) stock quote, history, news and other vital information to help you with your stock trading and investing.

      Sep 20Yahoo FinanceSLXN
      Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences

      Grand Cayman, Cayman Islands, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that members of its management team will participate in the following industry and investor conferences in September 2026: Oncology & Immunology Innovation Partnering & Licensing SummitPresentation date: September 9, 2026Location: Hotel

      Sep 9Yahoo FinanceSLXN
      After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLX
      Aug 25BenzingaSLXN
      Silexion Therapeutics Receives Nasdaq Delisting Notice, Plans Appeal

      Detailed price information for Silexion Therapeutics Corp (SLXN-Q) from The Globe and Mail including charting and trades.

      Aug 22The Globe and MailSLXN

      This is the newest page. Registered accounts read further back.